The University of Nottingham

Blood vessel protein could be harnessed to treat prostate tumours

November 10 2014 Research involving Nottingham academics has shown that a signal protein that plays a […]

Appears in Issue 5

Tags: anti-angiogenic, BBSRC, Biotechnology and Biological Sciences Research Council, Bristol University, Cancer Biology Unit, Dr Sebastian Oltean, new drugs, Oncogene, Oncology, proangiogenic, Professor David Bates, prognosis, prostate cancer, Prostate Cancer UK, research, Richard Bright VEGF Research Trust, School of Medicine, signal protein vascular endothelial growth factor